Alzheimer's Disease :: Baxter & Alzheimer's Disease Cooperative Study Group to pursue study of Gammagard Li

Alzheimer's disease, AD, or senile dementia of Alzheimer's type is a neurodegenerative disease which results in a loss of mental functions (dementia) due to the deterioration of brain tissue. Its exact etiology (cause) is still unknown, but environmental as well as genetic factors are thought to contribute.

Baxter & Alzheimer's Disease Cooperative Study Group to pursue study of Gammagard Liquid

Alzheimer's Disease :: Baxter & Alzheimer's Disease Cooperative Study Group to pursue study of Gammagard Liquid

Baxter International Inc. (NYSE: BAX) and The Alzheimer?s Disease Cooperative Study (ADCS) group announced the decision to pursue a multi-center U.S. Phase III study evaluating the role of Gammagard Liquid [Immune Globulin Intravenous (Human)] (IGIV) , an intravenous immunoglobulin preparation, for the treatment of patients with mild to moderate Alzheimer?s disease.

GAMMAGARD Liquid contains a broad spectrum of immunoglobulins (antibodies), and is indicated as an immunoglobulin replacement therapy in patients with primary immunodeficiency.

GAMMAGARD Liquid is processed from large pools of human plasma. IGIV has been used for almost three decades to treat primary immunodeficiency. IGIV is not currently approved for the treatment of Alzheimer?s disease, and to date has not been established to be effective in this indication.

The rationale for testing IGIV as a possible treatment for Alzheimer?s is based on the presence of natural antibodies that are directed against several forms of beta amyloid. Beta amyloid is a protein found in plaques that accumulate in the brains of patients with Alzheimer?s disease, and is considered to play a key role in the cognitive decline observed in these patients. Treatment with naturally occurring antibodies against beta amyloid contained in IGIV may result in clearance of beta amyloid from the brain and dissolution of plaques.

The decision to pursue the Phase III study is based on the results of two completed open-label clinical studies, and the preliminary analysis of interim data from a double-blind, placebo-controlled phase II study by Dr. Norman Relkin and his colleagues at Weill Cornell Medical College in New York City. In this study, 24 patients with mild to moderate Alzheimer?s disease were randomly assigned to receive GAMMAGARD Liquid, GAMMAGARD S/D or placebo (eight patients were treated with GAMMAGARD Liquid, eight patients were treated with GAMMAGARD S/D and eight patients received placebo) for six months. Cognitive, behavioral and functional measures were collected at baseline, three months and six months of treatment. The primary endpoints of the Phase II trial were cognitive function (as measured by ADAS-Cog score) and global function (as assessed by ADCS-CGIC rating). The pre-specified criterion for going forward with Phase III was a favorable outcome in IGIV-treated patients relative to those given placebo. Final results of the analysis of the Phase II study are expected later this year.

The Phase II study follows Dr. Relkin?s earlier Phase I results in eight patients that were reported at the International Conference on Alzheimer?s Disease in Madrid in July, 2006. Although these findings are promising, both studies were small and results must therefore be confirmed in a larger, sufficiently powered study.

The study protocol will be submitted to the U.S. Food and Drug Administration for review in the coming months with the intention of initiating patient recruitment early in 2008. The ADCS Phase III trial is sponsored jointly by the National Institutes of Health and Baxter. The trial will include approximately 35 leading academic centers in the U.S. that are members of ADCS.

(Alzheimer's Disease :: Baxter & Alzheimer's Disease Cooperative Study Group to pursue study of Gammagard Liquid published at SpiritIndia on Wednesday, August 29, 2007)

Alzheimer's Disease

Search more information on Alzheimer's Disease, Alzheimer's Disease books

Recently posted related articles on Alzheimer's Disease :

Most related articles:

Alzheimer's Disease - recent related articles/news stories:

- Mediterranean diet and exercise lower Alzheimer's disease risk
- Biomarkers may help predict risk of Alzheimer's disease
- Learning about Alzheimer's disease risk cause no distress
- Alzheimer's disease drug treats traumatic brain injury
- Structural MRI may diagnose dementia patients accurately

»» West Nile Virus :: FDA approves Roche's West Nile Virus screening test
«« Health :: Alberta to focus on five main areas to strengthen infection prevention and control

Tools
Daily calorie need
Homeo tips
Homeo softwares

Associations
NHMC Alumni
IFH
PHS
Vital Informer

Articles & news
Education
Homeo articles
Homeopathy cases
Homeopathic Remedies

You
Authors
Submit article
Your account
Testimonials

About
About us
Advertisers
Advertising
Linking us
Disclaimer
Privacy policy

The information provided on SpiritIndia.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. Spirit India comply with the HONcode principles for trustworthy health information.
Health, Business, Science, Sports, Entertainment, Technology
©2002-2009 SpiritIndia.com